[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fear-of-cancer-recurrence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fear-of-cancer-recurrence":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,43,76,107,129,158,185,209,233,260],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100610982","patient-partnered-research-in-investigating-fear-of-cancer-recurrence-in-kidney-cancer-100610982",false,"NCT07234656","Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer","Patient-partnered Research: a Key to Investigating Fear of Cancer Recurrence in Patients With Surgically Treated Kidney Cancer (PP-RECURK)","PP-RECURK","Inclusion Criteria:\n\nPhase 1:\n\n* Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner\u002Fspouse\n* Partner\u002Fspouse to patients who fullfil the inclusion criteria\n* Patients have undergone surgery due to localized RCC (T1-T2-T3 tumor)\n* Time since surgery: 0-120 months\n* Danish speaking patients and partners\u002Fspouses. Must be able to speak, write and read Danish\n* Patients\u002Fpartners\u002Fspouses able to and willing to attend online project meetings or in person at Gødstrup Hospital.\n\nPhase 2:\n\n* Single patients diagnosed with Renal Cell Carcinoma (RCC) or patients with RCC being in an intimate relationship with a partner\u002Fspouse\n* Partner\u002Fspouse to patients who fullfill the inclusion criteria\n* Patients who have undergone surgery due to localized RCC (T1-T2-T3 tumor)\n* Danish speaking patients and partners\u002Fspouses. Must be able to speak, write and read Danish\n* Able to receive digital communication from the hospital\n* Informed consent must be signed before answering Fear of Cancer Recurrence questions\n\nExclusion Criteria:\n\nBoth phases, both patients and partners\u002Fspouses:\n\n* Diagnosed with cognitive impairment\n* Untreated psychiatric disorders due to non-compliance\n\nPhase 2:\n\n• Patients and partners\u002Fspouses who were panelists in phase 1",true,"ALL",{"count":20,"type":21},105,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to gather real-world information about Fear of Cancer Recurrence (FCR) following surgery in patients with renal cell carcinoma (RCC) and their partners\u002Fspouses by 1) establishing a panel consisting of patients with or without partners\u002Fspouses to facilitate patient-partnered research. Furthermore, 2) Through discussions among panel members and researchers identification of the most pertinent topics related to FCR, as well as the optimal timing and methods for collecting that information in the follow-up care after surgery. Finally, to conduct a feasibility and pilot study to investigate the feasibility of the recommendations developed in 1) + 2) and assess FCR in patients with RCC following surgery and their partners\u002Fspouses.\n\nIn phase 1 participants (panel members) will be asked to collaborate with researchers in the development of recommendations for FCR questions, mode of administration and timing in the follow-up care after surgically treated kidney cancer.\n\nIn phase 2 participants (patients and partners) in follow-up care after surgically treated kidney cancer are asked to answer questions about FCR at specific timepoints defined by panel members and researchers in phase 1.",[25,26],"Fear of Cancer Recurrence","Renal Cell Carcinoma (Kidney Cancer)",[25,28,29],"Patient involvement in research","Kidney cancer","RECRUITING","2026-03-31",{"date":33,"type":34},"2026-04-01","ACTUAL",{"date":36,"type":34},"2025-09-30",{"date":38,"type":21},"2028-02",{"name":40,"class":41},"Brigitta Rasmussen Villumsen","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100578930","cognitive-behavioral-therapy-for-fear-of-cancer-recurrence-in-women-with-brca12-gene-100578930","NCT06817694","Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1\u002F2 Gene","CBT-FCRBRCA1\u002F2","Inclusion Criteria:\n\n* 1\\) Have completed primary treatment for breast or ovarian cancer (i.e., surgery, chemotherapy, and radiotherapy).\n* 2\\) Be known to carry a BRCA1\u002F2 pathogenic mutation.\n* 3\\) Have a clinical level of fear of cancer recurrence as defined by a score of 13 or more on the Fear of Cancer Recurrence Inventory severity subscale.\n* 4\\) Be at least 18 years of age.\n* 5\\) Be able to read, understand and express herself in French.\n\nExclusion Criteria:\n\n* 1\\) Have distant metastases (in the case of ovarian cancer, only stages IV and IIIC will be excluded).\n* 2\\) Be known to carry a BRCA1\u002F2 \"VUS\" mutation.\n* 3\\) Have a known cognitive disorder.\n* 4\\) Have a known severe psychological disorder (e.g., psychotic disorder, bipolar disorder, substance abuse or dependence disorder).\n* 5\\) Have already taken part in the original FCR group psychotherapy at the CHU de Québec.\n* 6\\) Women taking psychotropic medication are eligible, but only if the dosage has been stable for at least one month.","FEMALE","18 Years",{"count":53,"type":21},250,"INTERVENTIONAL",[56],"NA","The goal of this clinical trial is to determine whether an adapted version of a current cognitive-behavioural group therapy (CBT) protocol for cancer survivors to the specific needs of women who are carriers of the BRCA1\u002F2 genetic mutation will reduce their levels of fear of cancer recurrence. The main questions this study aims to answer are:\n\n* Will the women who have received the adapted CBT be satisfied with it?\n* Will there be a significant difference in the women's fear of cancer recurrence and other variables (e.g., depression, anxiety, insomnia, fatigue, quality of life) between the comparison groups?\n* Will the effects of the adapted CBT hold over time?\n* What are the roles of different etiological mediating variables in the relationship between fear of cancer recurrence and the effects of the adapted CBT on the severity of fear of cancer recurrence?\n\nResearchers will compare the effects of the adapted CBT between the immediate condition and the waitlist condition.\n\nParticipants will be:\n\n* Either placed in the immediate condition or the waitlist condition (the participants in the waitlist condition will begin their therapy once the immediate group is done with theirs).\n* Taking part in a group CBT session online once a week for eleven weeks.\n* Completing questionnaires pre-intervention, post-intervention, 3 months post-intervention, and 6 months post-intervention.",[59,60,25],"Breast Cancer Susceptibility Gene (BRCA1) Mutation","BRCA2 Mutation",[62,63,64,65,66],"BRCA1 Mutation","BRCA 2 Mutation","Fear of cancer recurrence","Cognitive-Behavioral Therapy","Cancer","2026-03-26",{"date":31,"type":34},{"date":70,"type":21},"2026-02",{"date":72,"type":21},"2028-12",{"name":74,"class":41},"CHU de Quebec-Universite Laval",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":54,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":75},"100631399","fighting-the-fear-of-cancer-recurrence-in-cancer-survivors-a-pilot-study-on-the-effectiveness-of-metacognitive-therapy-100631399","NCT07500168","Fighting the Fear of Cancer Recurrence in Cancer Survivors: A Pilot Study on the Effectiveness of Metacognitive Therapy","MCT-FCR","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Patients with cancer classified as stage I, II, or III according to the TNM staging system who have completed primary cancer treatment.\n3. Ability to understand and read Chinese, with no significant cognitive impairment.\n4. A score of 13 or higher on a validated measure of fear of cancer recurrence.\n\nExclusion Criteria:\n\n1. Individuals with severe psychiatric disorders.\n2. Individuals who have difficulty communicating in Mandarin. -",{"count":84,"type":21},120,[56],"This study aims to evaluate the effectiveness of metacognitive therapy (MCT) in reducing fear of cancer recurrence (FCR) among cancer survivors.\n\nWith advances in cancer treatment, more patients are surviving cancer. However, many survivors continue to experience fear of cancer recurrence, which can affect their emotional well-being, quality of life, and ability to return to normal daily activities.\n\nIn this study, participants will receive a structured psychological intervention adapted from the ConquerFear program. This program has been modified to better fit local cultural needs.\n\nParticipants will be randomly assigned to receive either metacognitive therapy or relaxation therapy.\n\nThe study will compare the effects of these interventions on reducing fear of cancer recurrence, as well as their impact on emotional distress and quality of life.\n\nThe results of this study may help develop effective psychological treatments to support cancer survivors in managing fear of recurrence and improving overall well-being.",[25,88,89],"Cancer Survivors","Psychological Distress",[25,88,91,92,93,94,95,96],"Psycho-oncology","ConquerFear","Randomized Controlled Trial","Anxiety","Depression","Quality of Life","NOT_YET_RECRUITING","2026-03-24",{"date":100,"type":34},"2026-03-30",{"date":102,"type":21},"2026-04",{"date":104,"type":21},"2028-12-31",{"name":106,"class":41},"Koo Foundation Sun Yat-Sen Cancer Center",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":54,"phases":116,"briefSummary":117,"conditions":118,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":75},"100531992","e-intervention-on-subclinical-fear-of-cancer-recurrence-100531992","NCT06207006","E-intervention on Subclinical Fear of Cancer Recurrence","Conquering Fear Online: a Pilot Randomised Controlled Trial Assessing the Efficacy and Feasibility of an Internet-based Self-management Intervention on Subclinical Fear of Cancer Recurrence","Inclusion Criteria:\n\n* Cantonese- or Mandarin-speaking Chinese cancer survivors\n* recently diagnosed with potentially curable (stage 0 to III) colorectal or breast cancer\n* had recently completed surgery as primary treatment\n* have completed hospital-based adjuvant treatments (including radiotherapy and chemotherapy) within the past six months\n* scored 13 to 21 on the fear of cancer recurrence-short form will be recruited.\n\nExclusion Criteria:\n\n* non-Chinese ethnicity\n* metastatic cancer\n* with current diagnosis of depression or psychosis or are currently receiving psychological treatments\n* language or intellectual difficulties that prevent them from understanding the intervention content\n* having limited or no Internet access.",{"count":115,"type":21},48,[56],"The present study aims to adapt a metacognition-based ConquerFear-HK to an internet-based self-management intervention, namely eConquerFear-HK and evaluate in a randomised controlled trial, its feasibility, utility, and potential effectiveness on fear of cancer recurrence reduction among local Chinese cancer survivors with subclinical fear of cancer recurrence.",[66,119,25],"Psychooncology","2025-10-01",{"date":122,"type":34},"2025-10-03",{"date":124,"type":34},"2024-05-02",{"date":126,"type":21},"2025-12-30",{"name":128,"class":41},"The University of Hong Kong",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":54,"phases":139,"briefSummary":140,"conditions":141,"keywords":145,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":75},"100583170","adapting-the-fear-of-recurrence-therapy-fort-for-parents-and-establishing-acceptability-and-feasibility-100583170","NCT06872840","Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility","Addressing Fear of Cancer Recurrence in Parents of Pediatric Cancer Survivors: Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility","Parent-FORT","Inclusion Criteria:\n\n* Parent (or primary caregiver) caring for a childhood cancer survivor (\\\u003C18 years of age) of any type of cancer type, who is at least 1 months from the completion of active treatment and has not had a recurrence of their cancer\n* A score of 13 or greater on the Fear of Cancer Recurrence Inventory-Short Form-Parent version (FCRI-SF-P; range 0-36), suggesting clinical levels of FCR\n* Access to a computer and internet connection\n* Living in Canada\n\nExclusion Criteria:\n\n* Being the parent of a pediatric cancer survivor who is now 18 years of age or older\n* Being the parent of a pediatric cancer survivor who has undergone hematopoietic cell transplantation and has active chronic or acute graft-versus-host disease which has not stabilized for at least 3 months\n* Non-English speakers\n* Currently participating in another therapist-led psychosocial therapy group\n* Parent with unmanaged\u002Fundermanaged mental health disorder judged to be clinically contraindicated and\u002For likely to affect the group work\n* To avoid violating the assumption of nonindependence of the data, only one parent\u002Fcaregiver per child can participate in the study.",{"count":138,"type":21},36,[56],"Clinical levels of fear of cancer recurrence (FCR) affect up to 59% of adult cancer survivors. Family caregivers experience equal or greater levels of FCR, which has been linked to lower quality of life and increased distress. FCR can be addressed in cancer survivors with brief interventions. However, none of these interventions have been tested with parents of childhood cancer survivors. This is an urgent gap: the survival rates of childhood cancer have increased more rapidly than for adult cancers, resulting in a growing population of childhood cancer survivors who, along with their families, need support.\n\nThe goals of this pilot study are to demonstrate 1) that a newly adapted intervention of FORT (Parent-FORT) is feasible (i.e., participant recruitment, attendance and participation) and acceptable (i.e., parent satisfaction of the intervention) for a larger study, and 2) the clinical implications of Parent-FORT on fear of cancer recurrence (FCR) and quality of life in parents of childhood cancer survivors.\n\nParents will be randomly assigned to participate in the Parent-FORT intervention immediately or a three-month waitlist control group. They will complete a questionnaire package before and after the intervention, as well as at a three month follow up. This study will help bridge an important gap in bringing evidence-based care to parents who have never been offered help before for their FCR.",[66,142,25,143,144],"Parent","CBT","Childhood Cancer Survivors",[146,147,148],"Pilot study","Group Therapy","Virtual","2025-09-16",{"date":151,"type":34},"2025-09-22",{"date":153,"type":34},"2025-08-26",{"date":155,"type":21},"2027-05-26",{"name":157,"class":41},"University of Ottawa",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":17,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":54,"phases":168,"briefSummary":169,"conditions":170,"keywords":172,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":75},"100602360","a-targeted-electronic-health-approach-to-reduce-fear-of-recurrence-in-breast-cancer-survivors-fortitude-100602360","NCT07122492","A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude)","Randomized Controlled Trial of FoRtitude: Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors in Community Oncology Settings","FoRtitude","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age.\n* Participant must have had histologically confirmed Stage 0-III breast cancer at time of diagnosis.\n* Participant must have completed primary treatment 1-10 years prior to Step 0 registration.\n\nNOTE: Current hormonal therapy is allowed. NOTE: Primary treatment can include chemotherapy and\u002For surgery and\u002For radiation therapy.\n\n\\- Participant must be receiving their care (cancer treatment or survivorship care) from an oncology provider affiliated with the NCORP site and are expected to continue care at the site for the next 18 months.\n\nNOTE: This eligibility criteria is intended to ensure access to healthcare utilization data. Oncology provider can include an Advance Practice Provider, Advance Nurse Practitioner, oncologist, primary care provider, or nurse or physician responsible for survivorship care.\n\n* Participant must have no evidence of active cancer of any type at the time of Step 0 registration (per the assessment of the physician), excluding local basal cell or squamous cell carcinoma.\n* Participant must be fluent in written and spoken English.\n* Participant must have an ECOG Performance Status of 0-2.\n* Participant must have the ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) are not eligible.\n* Participant must complete the FCRI 9-item severity scale and report a score of 13 or higher.\n* Participant must have access to the internet (via smartphone, tablet, or computer).\n\nNOTE: The restriction to those with internet access is based on the primary intention of the study which involves internet-based delivery intervention content delivered via the internet.\n\n* Participant must have completed the Baseline Assessment within 60 days of Step 0 registration.\n* Randomization to Step 1 must occur within 60 days of Step 0 registration.\n\nExclusion Criteria:\n\n* Participant must not have any psychiatric or cognitive conditions that may affect the participant's ability to accurately provide self-report data, per clinical discretion.",{"count":167,"type":21},800,[56],"The goal of this study is to determine if the intervention or if general information about being a breast cancer survivor can help Breast Cancer Survivors reduce their fear of recurrence. The main question it aims to answer are:\n\nCan the FoRtitude intervention lower the fear of recurrence for Breast Cancer Survivors?\n\nParticipants will:\n\nAnswer questions about their fear of recurrence. Be randomized to 1 of the 3 following options: (1) a weblink to access an eHealth intervention which includes a website and an optional interactive text-messaging feature, (2) a weblink to a non-interactive website that will include links to external websites with general information that may be helpful for Breast Cancer Survivors, or (3) you will need to talk with your oncology team about your concerns about recurrence or seek psychosocial care in the community.\n\nBe asked to fill out questionnaires 5 times for up to 18 months.",[171,25],"Breast Cancer Survivor",[173,174],"Breast cancer survivor","Fear of recurrence","2025-08-07",{"date":177,"type":34},"2025-08-14",{"date":179,"type":21},"2025-09-01",{"date":181,"type":21},"2029-09-01",{"name":183,"class":184},"Eastern Cooperative Oncology Group","NETWORK",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":54,"phases":194,"briefSummary":195,"conditions":196,"keywords":197,"overallStatus":97,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":75},"100530019","the-effect-of-a-stepped-care-metacognition-based-intervention-on-managing-fear-of-cancer-recurrence-100530019","NCT06181331","The Effect of a Stepped-care Metacognition-based Intervention on Managing Fear of Cancer Recurrence","The Effect of a Stepped-care Metacognition-based Intervention on Managing Fear of Cancer Recurrence: Sequential, Multiple Assignment, Randomized Controlled Trial (SMARTs)","Inclusion Criteria:\n\n* Cantonese- or Mandarin-speaking Chinese patients diagnosed with curable breast, colorectal, or gynecological cancer, who had completed treatment (except endocrine therapy) within five years, and with a Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF) score of 13 to 21 indicating subclinical FCR will be included.\n\nExclusion Criteria:\n\n* Patients with metastatic cancer, with a current diagnosis of depression or psychosis, or who are already receiving psychological treatment will be excluded.",{"count":193,"type":21},300,[56],"A sequential multiple-assignment randomized controlled trial (SMART) will be used to assess the effect of an adaptive stepped-care intervention on FCR in cancer survivors with subclinical levels of fear of cancer recurrence.",[66,25],[198,199,200],"Sequential multiple assessment randomized controlled trial","stepped-up care","psychooncology","2025-06-09",{"date":203,"type":34},"2025-06-11",{"date":205,"type":21},"2026-01-01",{"date":207,"type":21},"2027-12-31",{"name":128,"class":41},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":54,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},"100530020","implementation-and-evaluation-of-a-fear-of-cancer-recurrence-screening-referral-and-management-program-100530020","NCT06181344","Implementation and Evaluation of a Fear of Cancer Recurrence Screening, Referral and Management Program","Implementation and Evaluation of a Fear of Cancer Recurrence Screening, Referral and Management Program for Chinese Cancer Survivors: a Stepped Wedge and Cluster Randomized Trial","Inclusion Criteria:\n\n* All patients diagnosed with non-metastatic breast, gynecological, or colorectal cancer, and who have completed primary and adjuvant treatment within the past two years will be eligible for the proposed screening program.\n\nExclusion Criteria:\n\n* All cancer patients beyond two years post-treatment; and diagnosed with metastatic cancer or non-breast, non-gynecological, and non-colorectal cancer.",{"count":217,"type":21},1980,[56],"The purpose of this study is to evaluate the process and outcomes of an implementation program designed to implement fear of cancer screening, referral and management into routine cancer care clinics, using a stepped-wedge cluster randomized controlled trial.",[25,66],[222,223],"implementation study","Screening and referral program","2025-01-09",{"date":226,"type":34},"2025-01-13",{"date":228,"type":34},"2024-07-26",{"date":230,"type":21},"2026-08-31",{"name":128,"class":41},2,{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":54,"phases":242,"briefSummary":243,"conditions":244,"keywords":248,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":232},"100575057","emdr-for-fear-of-cancer-recurrence-in-patients-with-familial-melanoma-a-waiting-list-control-trial-100575057","NCT06767332","EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial","FAME","Inclusion Criteria:\n\n* a score of 16 or higher on the FCRI-NL-SF\n* 18 years or older\n* diagnosed with familial melanoma\n\nExclusion Criteria:\n\n* insufficient knowledge of the Dutch language.\n* acute psychiatric disease (psychosis, suicidal ideation)\n* variable dosis of anxiolytics",{"count":241,"type":21},30,[56],"High fear of cancer recurrence (FCR) impacts patient's quality of life (QoL) and is prevalent among patients with familial melanoma. The main objective is to investigate whether EMDR is effective in treating high FCR in patients with familial melanoma. The study design is a non-blinded, randomized waiting-list controlled trial. Patients aged 18 years or older with familial melanoma can be included. Patients with high FCR will receive a maximum of 4, 90 minutes, EMDR-sessions. The main study parameter is the decrease and level of FCR measured with the Cancer Worry Scale (CWS). The secondary study parameter is quality of life, measured with the EORTC.",[245,25,246,247],"Familial Melanoma","Eye Movement Desensitization and Reprocessing","Psychological Intervention",[249,25,245,246,250,94,91,251],"EMDR","Psychological intervention","FCR","2025-01-08",{"date":224,"type":34},{"date":255,"type":34},"2023-11-01",{"date":257,"type":21},"2025-12-31",{"name":259,"class":41},"Leiden University Medical Center",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":54,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":75},"100558728","cifer---a-clinician-led-intervention-to-address-fear-of-cancer-recurrence-100558728","NCT06554899","CIFeR - A Clinician-led Intervention to Address Fear of Cancer Recurrence","The Efficacy of a Brief Oncologist-delivered Intervention for Fear of Cancer Recurrence: A Cluster-randomized Controlled Trial","Inclusion Criteria:\n\n* Are ≥ 18 years old\n* Have completed their primary treatment, i.e., surgery, adjuvant chemotherapy, and\u002For radiotherapy, for breast, ovarian, prostate, or lung cancer at the participating departments between three weeks and three months previously.\n* Score \\>= 13 on the FCRI-SF\n\nExclusion Criteria:\n\n\\-",{"count":193,"type":21},[56],"The investigators will test a novel Clinician-led Intervention to address Fear of cancer Recurrence in cancer survivors (CIFeR), by 1) adapting the original Australian intervention manual to the Danish oncology context (CIFeR-DK), and 2) developing a brief e-learning program to train oncologists. The investigators will then 3) compare CIFeR-DK with an active control condition in a cluster-randomized controlled trial with 24 oncologists (the cluster unit) treating a minimum of 300 patients with breast, ovarian, lung and prostate cancer at Danish Oncology Departments at four hospitals in Aarhus, Vejle, Aalborg, and Copenhagen, and 4) explore fidelity, acceptability, feasibility, and perceived barriers and facilitators to use the intervention in routine follow-up care.",[25],"2024-08-19",{"date":273,"type":34},"2024-08-21",{"date":275,"type":34},"2024-06-14",{"date":277,"type":21},"2026-06-01",{"name":279,"class":41},"Aarhus University Hospital"]